3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow Bioeq GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Double-blind Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara® in Patients With Moderate-to-Severe Plaque Psoriasis FYB202 (Proposed ustekinumab biosimilar), Stelara® (Ustekinumab) - Plaque Psoriasis | Phase 3 | Completed | Bioeq GmbH | 392 | 2020-11-09 | 2023-02-16 |
| Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration FYB203 (Proposed aflibercept biosimilar), Eylea® (Aflibercept) - Neovascular Age-related Macular Degeneration | Phase 3 | Completed | Bioeq GmbH | 434 | 2020-07-21 | 2025-11-13 |
| Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration ranibizumab - Age-related Macular Degeneration (AMD) | Phase 3 | Completed | Bioeq GmbH | 712 | 2015-12-19 | 2021-09-30 |
Ranibizumab (1) · Ustekinumab (1) · aflibercept (1)
Poland (3) · Ukraine (3) · Czechia (2) · Hungary (2) · Israel (2) · Italy (2) · Russia (2) · Austria (1) · Bulgaria (1) · Estonia (1) · France (1) · Georgia (1) · Germany (1) · Japan (1) · Spain (1)